Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06825689 · ClinicalTrials.gov registry record · NA
Unidos Contra el VPH
A NA study of Human Papilloma Virus (HPV) and Cervical Cancers, sponsored by University of Texas at Austin.
- Recruiting
- Registry status
- NA
- Development phase
- 735
- Enrollment target
- 1
- Study location
NCT06825689: Recruiting NA study of Human Papilloma Virus (HPV) and Cervical Cancers, sponsored by University of Texas at Austin.
NCT06825689 is a NA study of Human Papilloma Virus (HPV) and Cervical Cancers that is actively recruiting participants, run by University of Texas at Austin. The registered enrollment target is 735 participants, above the 166-participant average among 3 other Human Papilloma Virus (HPV) trials with a reported enrollment target (343% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06825689, a NA study of Human Papilloma Virus (HPV) and Cervical Cancers, is actively recruiting participants, sponsored by University of Texas at Austin.
- RECRUITING
- Registry status
- NA
- Development phase
- 735 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the Unidos Contra el VPH study is to help find options to screen, or check, for cervical cancer that individuals can do at home to help prevent and detect cervical cancer early. Usually, people get screened for cervical cancer with a Pap smear and human papillomavirus (HPV) test by a health care provider. This is not always easy for individuals who are not able to get to a clinic or feel uncomfortable having the procedure done. That is why we want to find other ways that may be easier and more comfortable for people to be screened for cervical cancer. The two main questions the study aims to answer are: 1. How do the following three cervical cancer screening methods compare for improving screening completion rates? o In-home HPV self-sampling with a vaginal swab * In-home HPV self-sampling with urine testing * In-clinic traditional Pap smear with HPV test 2. What are participant beliefs and preferences regarding these three screening methods? Participants in the study will be randomly assigned to one of three groups. This means each person has an equal chance of being placed in any group. They will also complete two surveys as part of the study. The three screening method groups are described below: Group 1: Urine Self-Sampling * Participants in this group will receive a kit with a urine sample cup to use at home, instructions explaining how to take the sample and a pre-paid mailing box to mail the urine sample to the lab. Group 2: Vaginal Swab Self-Sampling o Participants in this group will receive a kit with a vaginal swab and collection tube to use at home, instructions explaining how to take the sample and a pre-paid mailing box to mail the sample to the lab. Group 3: In-Clinic Screening * An in-clinic co-testing appointment is scheduled for a Pap smear and HPV test done together at Project Vida Health Center. By comparing these approaches, this study aims to improve access to cervical cancer screening and pro
Primary Outcome
This study will compare the effectiveness of three cervical cancer screening methods in achieving screening completion. Participants will be randomized to one of the following groups: In-home HPV self-sampling using a urine sample In-home HPV self-sampling using a cervico-vaginal swab In-clinic cervical cancer screening via clinician-collected HPV and Pap test The primary outcome will be the screening completion rate-- the proportion of participants who successfully complete their assigned scr
Conditions Studied
Interventions
- DEVICE Self-sampling with urine
- DEVICE Self-sampling with swab
- DEVICE In-clinic Pap/HPV co-testing
Study Locations (1)
Texas
- Project Vida Health Center - El Paso
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 735 participants |
| Start Date | 2025-01-28 |
| Est. Completion | 2029-02 |
| Phase | NA |
What NCT06825689 shows while recruiting
NCT06825689 is an interventional study that assigns participants to a tested intervention. The registered 735 participants enrollment target is mid-sized for trials with a published cap, above the 166-participant average among 3 other Human Papilloma Virus (HPV) trials with a reported enrollment target (343% higher).
The record links to 2 conditions, with Human Papilloma Virus (HPV) appearing as the primary indexed condition, and to 3 interventions - of which Self-sampling with urine is the first listed.
NCT06825689 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06825689 about?
NCT06825689 is a clinical study titled "Unidos Contra el VPH". The purpose of the Unidos Contra el VPH study is to help find options to screen, or check, for cervical cancer that individuals can do at home to help prevent and detect cervical cancer early. Usually, people get screened for cervical cancer with a Pap smear and human papillomavirus (HPV) test by a ...
What is the current status of trial NCT06825689?
This trial is currently recruiting. It is a NA study. The enrollment target is 735 participants. The study started on 2025-01-28. Estimated completion is 2029-02.
What conditions does trial NCT06825689 study?
This clinical trial studies the following conditions: Human Papilloma Virus (HPV), Cervical Cancers.
What interventions are being tested in trial NCT06825689?
The interventions under investigation include: Self-sampling with urine (DEVICE), Self-sampling with swab (DEVICE), In-clinic Pap/HPV co-testing (DEVICE).
Who is sponsoring clinical trial NCT06825689?
This trial is sponsored by University of Texas at Austin, which has 257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06825689 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Papilloma Virus (HPV)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Using Plasma Human Papillomavirus (HPV)-Related Deoxyribonucleic Acid (DNA) and Ribonucleic Acid (RNA) to Follow Response of Cervical Cancer to Surgery, Radiation, and Chemotherapy
RECRUITING
-
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)
RECRUITING · Phase 3
-
New Strategies to Assess Anal Cancer Risk In Women
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05947851 · 735 participants · Phase 3
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- NCT05999084 · 735 participants
Georgia Memory Net Anti-Amyloid Monoclonal Antibody Registry
- NCT05796141 · 736 participants · NA
Becoming United in Lifestyle Decisions
- NCT06216301 · 734 participants · Phase 3
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI